Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
02/20/20187:30AMPRNUSMylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program - DTG/FTC/TAF is comprised of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg - - Mylan's DTG/FTC/TAF will be the first TAF-based fixed-dose combination to be offered to patients in... More...>>
02/08/201811:45AMPRNUSMylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018
Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018 PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Feb. 8, 2018 HERTFORDSHIRE, England, and PITTSBURGH, Feb. 8, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will release its fourth quarter and... More...>>
02/01/20187:30AMPRNUSMylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets
Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets - Launch further strengthens Mylan's leading antiretroviral portfolio - - Mylan is eligible for 180 days of exclusivity - PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 1, 2018 HERTFORDSHIRE, England and PITTSBURGH, Feb... More...>>
01/29/20188:30AMPRNUSTheravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chron...
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease FDA Assigns PDUFA Target Action Date of November 13, 2018 PR Newswire DUBLIN, HERTFORDSHIRE, England and PITTSBURGH, Jan. 29, 2018 DUBLIN, HERTFORDSHIRE, England... More...>>
01/29/20188:30AMPRNUSTheravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chron...
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease FDA Assigns PDUFA Target Action Date of November 13, 2018 PR Newswire DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Jan. 29, 2018 DUBLIN and HERTFORDSHIRE, England... More...>>
01/29/20186:00AMPRNUSMylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine
Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine First biosimilar from Mylan and Biocon's joint portfolio recommended for approval in the European Union (EU) PR Newswire HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Jan. 29, 2018 HERTFORDSHIRE, England and PITTSBURGH... More...>>
01/08/20187:30AMPRNUSMylan to Complete $1 Billion Share Repurchase Plan
Mylan to Complete $1 Billion Share Repurchase Plan Abbott sells remaining 20.3 million shares of Mylan PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2018 HERTFORDSHIRE, England and PITTSBURGH, Jan. 8, 2018 /PRNewswire/ -- Global pharmaceutical leader Mylan N.V. (NASDAQ, TASE: MYL) today announced that it... More...>>
01/03/20184:05PMPRNUSMomenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept) -- Targeting the initiation of a pivotal patient clinical trial in the first half of 2018 -- PR Newswire CAMBRIDGE, Mass. and HERTFORDSHIRE, England and PITTSBURGH, Jan. 3, 2018 CAMBRIDGE, Mass. and HERTFORDSHIRE, England and... More...>>
01/03/20184:05PMGLOBEMomenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
CAMBRIDGE, Mass., HERTFORDSHIRE, United Kingdom and PITTSBURGH, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL) today announced the development strategy for M710, a proposed biosimilar to EYLEA® (aflibercept) injection. EYLEA is the market-leading vascular... More...>>
12/29/201710:47AMPRNUSMylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace® Cream
Mylan Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Generic for Estrace® Cream Mylan now offers estradiol in four delivery methods The approval showcases Mylan's ongoing investment in complex products PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2017 HERTFORDSHIRE, England and PITTSBURGH... More...>>
12/29/20171:30AMPRNUSBiocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs PR Newswire BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH and SAO PAULO, Dec. 29, 2017 BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH and SAO PAULO, Dec. 29, 2017 /PRNewswire/ -- Biosimilar... More...>>
12/20/201712:00PMPRNUSMylan to Present at the 36th Annual J.P. Morgan Healthcare Conference
Mylan to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 20, 2017 HERTFORDSHIRE, England and PITTSBURGH, Dec. 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its CEO, Heather Bresch, will present at the 36th Annual J.P. Morgan... More...>>
12/20/20177:30AMPRNUSMylan to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Mylan to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 20, 2017 HERTFORDSHIRE, England and PITTSBURGH, Dec. 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its CEO, Heather Bresch, will present at Goldman Sachs... More...>>
12/14/20177:30AMPRNUSMylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against S...
Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus® Patents PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 14, 2017 HERTFORDSHIRE, England and PITTSBURGH, Dec. 14, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today... More...>>
12/11/201712:16PMPRNUSTeva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone® 40 mg/m...
Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone® 40 mg/mL Teva also agrees to withdraw Irish equivalent to U.S. patents from litigation in Ireland PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 11, 2017 HERTFORDSHIRE, England and PITTSBURGH... More...>>
12/05/20176:22AMDJNRoche's Breast Cancer Drug Herceptin Faces Biosimilar Competition -Cinco Dias
--Within a few weeks of each other, the U.S. Food and Drug Administration and the European Medicines Agency have approved the authorization of the sale of Herceptin biosimilars, Spain's Cinco Dias reports. --Herceptin is a drug developed by Roche Holding AG (ROG.EB) for the treatment breast cancer. --Cinco Dias says... More...>>
12/04/20177:30AMPRNUSMylan and Aspen Announce Launch of Generic Busulfex® Injection
Mylan and Aspen Announce Launch of Generic Busulfex® Injection PR Newswire HERTFORDSHIRE, England, PITTSBURGH and DURBAN, South Africa, Dec. 4, 2017 HERTFORDSHIRE, England, PITTSBURGH and DURBAN, South Africa, Dec. 4, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and its partner, Aspen (JSE: APN), today announced... More...>>
12/01/201711:31AMPRNUSU.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Brea...
U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers Mylan anticipates potentially being the first company to provide patient access to a biosimilar to Herceptin®, representing a significant milestone for Mylan, Biocon and the... More...>>
12/01/201710:50AMPRNUSFDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan's Deep Expertise in Developing Complex Products
FDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan's Deep Expertise in Developing Complex Products PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 1, 2017 HERTFORDSHIRE, England and PITTSBURGH, Dec. 1, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), a global pharmaceutical company, today... More...>>
11/30/201712:55PMPRNUSEuropean Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Trastuzuma...
European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Trastuzumab and Pegfilgrastim PR Newswire HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Nov. 30, 2017 HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Nov. 30, 2017 /PRNewswire/ -- Mylan... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V:us D:20180221 09:29:38